|Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful...||Aspirin, Laboratory Biomarker Analysis, Placebo Administration, Questionnaire Administration||NCT02521285||National Cancer Institute (NCI)||Active, not recruiting|
|Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma||Aspirin, Laboratory Biomarker Analysis, Placebo Administration, Questionnaire Administration||NCT02965703||National Cancer Institute (NCI)||Active, not recruiting|
|An Internet-based Program to Help Cancer Survivors Manage Pain||Internet-based pain coping skills program||NCT04462302||Wake Forest University Health Sciences||Recruiting|
|Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II...||Exemestane, Laboratory Biomarker Analysis, Pharmacological Study, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration, Therapeutic Conventional Surgery||NCT02598557||National Cancer Institute (NCI)||Active, not recruiting|
|Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast||Afimoxifene, Laboratory Biomarker Analysis, Placebo, Questionnaire Administration||NCT03063619||M.D. Anderson Cancer Center||Active, not recruiting|
|Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer...||Best Practice, Educational Intervention, Motivational Interviewing, Quality-of-Life Assessment, Questionnaire Administration, Text Message-based Navigation Intervention||NCT04379570||Alliance for Clinical Trials in Oncology||Recruiting|
|Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts||Contrast-enhanced Magnetic Resonance Imaging, Digital Tomosynthesis Mammography, Quality-of-Life Assessment, Questionnaire Administration||NCT02933489||ECOG-ACRIN Cancer Research Group||Active, not recruiting|
Why I Joined a Clinical TrialI was the first patient who Dr. Abraham enrolled on the NSABP B-31 clinical trial (chemo vs chemo + Trastuzumab in HER-2 positive breast cancer). I am grateful to him for presenting me with the opportunity to join the study 20 years ago in March 2001 and that I had the courage to participate, as I continue to do well to this day. This clinical trial ended up changing the landscape of treatment for future patients with breast cancer.